MIRA Pharmaceuticals (NASDAQ:MIRA) | WebDisclosure

Basculer en Français

9475	Companies
185442	Keywords
117781	Articles
99296	Press releases

Home
Companies
MIRA Pharmaceuticals

PRESS RELEASE

published on 05/08/2025 at 14:00, 6 months 27 days ago

MIRA Pharmaceuticals Announces Board Approval of SKNY Acquisition Reflecting $60+ Million in Combined Enterprise Value Based on Independent Review
MIRA Pharmaceuticals, Inc. announces board approval for strategic acquisition of SKNY Pharmaceuticals targeting obesity and nicotine dependence. $5 million contribution from SKNY. Merger subject to shareholder approval

Acquisition Obesity MIRA Pharmaceuticals SKNY Pharmaceuticals Nicotine Dependence
BRIEF

published on 05/06/2025 at 14:05, 6 months 29 days ago

MIRA Pharmaceuticals Announces Absence of Neurotoxicity in Ketamir-2 Study

Phase I Trial MIRA Pharmaceuticals Ketamir-2 NMDA Receptor Neurotoxicity Study
BRIEF

published on 05/06/2025 at 14:05, 6 months 29 days ago

MIRA Pharmaceuticals annonce l'absence de neurotoxicité dans l'étude Ketamir-2

Essai De Phase I MIRA Pharmaceuticals Ketamir-2 Récepteur NMDA Étude De Neurotoxicité
PRESS RELEASE

published on 05/06/2025 at 14:00, 6 months 29 days ago

MIRA Pharmaceuticals Reports No Brain Toxicity in FDA-Required Study of Ketamir-2, Confirming Absence of Ketamine-Linked Neurotoxicity
MIRA Pharmaceuticals announces positive preclinical results for oral NMDA receptor antagonist Ketamir-2, showing no brain toxicity. Phase I clinical trial ongoing

Phase I Clinical Trial Preclinical Results MIRA Pharmaceuticals Ketamir-2 Oral NMDA Receptor Antagonist
BRIEF

published on 04/23/2025 at 14:05, 7 months 11 days ago

MIRA Pharmaceuticals Announces Promising Results for Ketamir-2 Topical Formulation

FDA Fast Track Ketamir-2 Topical Formulation In Vitro Testing Pain Relief Market
BRIEF

published on 04/23/2025 at 14:05, 7 months 11 days ago

MIRA Pharmaceuticals annonce des résultats prometteurs pour la formulation topique du kétamir-2

Procédure Accélérée De La FDA Ketamir-2 Formulation Topique Tests In Vitro Marché Du Soulagement De La Douleur
PRESS RELEASE

published on 04/23/2025 at 14:00, 7 months 11 days ago

MIRA Pharmaceuticals Reports Positive In Vitro Drug Release Data for Topical Ketamir-2, Targeting $11B+ U.S. Topical Pain Relief Market and Exploring FDA Fast Track Designation
MIRA Pharmaceuticals announces completion of IVRT for topical Ketamir-2 formulation in pain-related conditions, aiming to address market needs and regulatory considerations

MIRA Pharmaceuticals Neuropathic Pain Topical Formulation IVRT FDA Guidance
BRIEF

published on 04/16/2025 at 14:05, 7 months 18 days ago

MIRA Pharmaceuticals Reports Promising Ketamir-2 Data for Diabetic Neuropathy

Clinical Trials MIRA Pharmaceuticals Ketamir-2 Diabetic Neuropathy Non-Opioid Treatments
BRIEF

published on 04/16/2025 at 14:05, 7 months 18 days ago

MIRA Pharmaceuticals publie des données prometteuses sur le kétamir-2 pour la neuropathie diabétique

Essais Cliniques MIRA Pharmaceuticals Ketamir-2 Neuropathie Diabétique Traitements Non Opioïdes
PRESS RELEASE

published on 04/16/2025 at 14:00, 7 months 18 days ago

MIRA Pharmaceuticals Announces Positive Results for Ketamir-2 in Diabetic Neuropathy Animal Model, Reinforcing Confidence Ahead of Phase I Completion
MIRA Pharmaceuticals announces strong efficacy of Ketamir-2 in diabetic neuropathy model, offering potential breakthrough treatment for patients. Phase IIa trial planned

Clinical Trial MIRA Pharmaceuticals Ketamir-2 Neuropathic Pain Diabetic Neuropathy

Accesswire

Published on 12/05/2025 at 02:35, 8 hours 49 minutes ago

Future Fuels Initates Drill Permitting at Hornby; Marketing Update
Published on 12/05/2025 at 02:30, 8 hours 54 minutes ago

Klondike Gold Announces AGM Results
Published on 12/05/2025 at 01:00, 10 hours 24 minutes ago

BEACN Closes First Tranche of Non-Brokered Private Placement
Published on 12/04/2025 at 23:05, 12 hours 19 minutes ago

BlackBerry to Announce Third Quarter Fiscal Year 2026 Results on December 18, 2025
Published on 12/04/2025 at 23:00, 12 hours 24 minutes ago

NXT Energy Solutions Completes Data Acquisition for SFD Survey

View all ACCESSWIRE

EQS Group

Published on 12/05/2025 at 11:14, 10 minutes ago

Halfords Group PLC: Director/PDMR Shareholding
Published on 12/05/2025 at 11:08, 15 minutes ago

Linedata Services: Information mensuelle relative au nombre total de droits de vote et d'actions composant le capital social
Published on 12/05/2025 at 10:30, 54 minutes ago

Tradegate Exchange and Börse Berlin merge to form Tradegate BSX
Published on 12/05/2025 at 10:15, 1 hour 9 minutes ago

Wuxi’s Liangxi District: Where 3,000 Years of Jiangnan Culture Thrives
Published on 12/05/2025 at 09:40, 1 hour 44 minutes ago

Chery Partners with 2025 Asian Youth Para Games, Taking Center Stage in Global Sports with Passion and Aspiration

Les Echos

Published on 12/05/2025 at 08:45, 2 hours 39 minutes ago

Air Liquide va étendre et électrifier son unité de production d'oxygène à Shaanxi, soutenant ainsi l'engagement de la Chine à décarboner son industrie
Published on 12/05/2025 at 08:45, 2 hours 39 minutes ago

Air Liquide to expand and electrify its oxygen facility in Shaanxi, supporting China’s commitment to decarbonize its industry
Published on 12/05/2025 at 08:42, 2 hours 42 minutes ago

ENGIE - déclaration mensuelle du nombre total d'actions et de droits de vote composant le capital au 30 novembre 2025
Published on 12/04/2025 at 18:14, 17 hours 9 minutes ago

Résiliation d'une convention conclue entre actionnaires
Published on 12/04/2025 at 18:00, 17 hours 24 minutes ago

Informations relatives au nombre total de droits de vote et d’actions composant le capital social au 28 novembre 2025

View all LES ECHOS COMFI WIRE